{"version":"1.0","type":"link","title":"Phase II study of FOLFIRI with low-dose irinotecan plus ramucirumab as second-line treatment in Japanese patients with metastatic colorectal cancer (study rindo).","author_name":"Hattori N 외","author_url":"https://prs-insight.online/author/Hattori%20N","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/104351","thumbnail_width":1200,"thumbnail_height":630}